These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 36982234)
1. Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer. Tribukait B; Lundgren PO; Kjellman A; Norming U; Nyman CR; Jagarlmundi K; Gustafsson O Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982234 [TBL] [Abstract][Full Text] [Related]
2. The combination of AroCell TK 210 ELISA with Prostate Health Index or prostate-specific antigen density can improve the ability to differentiate prostate cancer from noncancerous conditions. Jagarlamudi KK; Zupan M; Kumer K; Fabjan T; Hlebič G; Eriksson S; Osredkar J; Smrkolj T Prostate; 2019 Jun; 79(8):856-863. PubMed ID: 30889628 [TBL] [Abstract][Full Text] [Related]
3. Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker. Jagarlamudi KK; Hansson LO; Eriksson S BMC Cancer; 2015 Feb; 15():66. PubMed ID: 25881026 [TBL] [Abstract][Full Text] [Related]
4. Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer. Lundgren PO; Tribukait B; Kjellman A; Norming U; Jagarlmudi K; Gustafsson O Prostate; 2022 Jun; 82(8):911-916. PubMed ID: 35294068 [TBL] [Abstract][Full Text] [Related]
5. Analytical and clinical characterization of an optimized dual monoclonal sandwich ELISA for the quantification of thymidine kinase 1 (TK1) protein in human blood samples. Jagarlamudi KK; L S; M Z; J O; P V; S E PLoS One; 2022; 17(10):e0275444. PubMed ID: 36201558 [TBL] [Abstract][Full Text] [Related]
6. Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer. de Vries SH; Raaijmakers R; Blijenberg BG; Mikolajczyk SD; Rittenhouse HG; Schröder FH Urology; 2005 May; 65(5):926-30. PubMed ID: 15882725 [TBL] [Abstract][Full Text] [Related]
7. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Assel M; Dahlin A; Ulmert D; Bergh A; Stattin P; Lilja H; Vickers AJ Eur Urol; 2018 Jun; 73(6):961-967. PubMed ID: 29066048 [TBL] [Abstract][Full Text] [Related]
8. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening. Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075 [TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
10. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027 [TBL] [Abstract][Full Text] [Related]
11. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase. Xie W; Nakabayashi M; Regan MM; Oh WK Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608 [TBL] [Abstract][Full Text] [Related]
12. Thymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker. Jagarlamudi KK; Shaw M Biomark Med; 2018 Sep; 12(9):1035-1048. PubMed ID: 30039979 [TBL] [Abstract][Full Text] [Related]
13. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial. Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332 [TBL] [Abstract][Full Text] [Related]
14. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy]. Popov SV; Guseinov RG; Skryabin ON; Orlov IN; Martov AG Urologiia; 2018 Jul; (3):92-97. PubMed ID: 30035426 [TBL] [Abstract][Full Text] [Related]
15. Expression and Clinical Significance of Cytokeratin-19 and Thymidine Kinase-1 in Advanced Gastrointestinal Cancer. Du YY; Zhang QJ; Sun GP Chin Med J (Engl); 2016 Sep; 129(18):2168-72. PubMed ID: 27625087 [TBL] [Abstract][Full Text] [Related]
16. A novel algorithm for the prediction of prostate cancer in clinically suspected patients. Gallotta A; Ziglioli F; Ferretti S; Maestroni U; Moretti M; Aloe R; Gnocchi C; Di Palo M; Fassina G Cancer Biomark; 2013; 13(4):227-34. PubMed ID: 24240583 [TBL] [Abstract][Full Text] [Related]
17. Relationship between thymidine kinase 1 before radiotherapy and prognosis in breast cancer patients with diabetes. Wang Z; Zhang W; Huo B; Dong L; Zhang J Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32202305 [TBL] [Abstract][Full Text] [Related]
18. Clinical significance of prostate specific antigen for early stage prostate cancer detection. Imai K; Ichinose Y; Kubota Y; Yamanaka H; Sato J; Saitoh M; Watanabe H; Ohe H Jpn J Clin Oncol; 1994 Jun; 24(3):160-5. PubMed ID: 7516445 [TBL] [Abstract][Full Text] [Related]